| |
|
Headlines:
|
 |
Back
to index
5-fluorouracil, doxorubicin, and cisplatin (FAP) regimen
Abstract: A phase II study of combined 5-fluorouracil, doxorubicin,
and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.
In a phase II study of 67 patients
with upper gastrointestinal carcinomas and measurable disease without
previous chemotherapy, we have evaluated the combination of intensive course
5-fluorouracil (5-FU) (300 mg/m2/d for five days) doxorubicin (40 mg/m2
on day 1), and cisplatin (60 mg/m2 on day 1). Courses were repeated every
5 weeks. Among 26 patients with gastric carcinoma, a
50% regression rate was obtained with
a median survival for all patients of 9 months.
Among 29 patients with pancreatic carcinoma, the regression rate was 21%
and the median survival was 4 months. Regressions were also observed in
smaller numbers of patients with carcinomas of the gallbladder and ampulla
of Vater, as well as in cholangiocellular carcinoma of the liver. Toxic
reactions were usually clinically tolerable and consisted primarily of nausea,
vomiting, stomatitis,
diarrhea, leukopenia, and alopecia. Phase III studies
are in progress to place the value of this experimental regimen into clinical
perspective.
References
Moertel CG, Rubin J, O'Connell MJ, Schutt AJ, Wieand HS. A phase II study
of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment
of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol; 4(7):1053-7
1986.
|
|
|
|
Are you a doctor or a nurse?
Do you want to join the Doctors Lounge online medical community?
Participate in editorial activities (publish, peer review, edit) and
give a helping hand to the largest online community of patients.
Click on the link below to see the requirements:
Doctors Lounge Membership
Application |
|
| Regimen |
|
5 - FU....... 300 mg/m2/d days
1-5
Doxorubicin....... 40 mg / M2 IV day 1
Cisplatin....... 60 mg / M2 IV day 1
FREQUENCY every 5 weeks. |
|
|
| |
|
|
| |
Summary |
Phase
II study of combined 5FU, doxorubicin, and cisplatin for gastric cancer |
| |
Regression
Rate |
50% |
| |
Median Survival |
9 months |
| |
Toxicity |
Nausea, vomiting,
stomatitis,
diarrhea, leukopenia, and alopecia. |
| |
|
|
|
|
send
to a friend
printer
friendly version
